Elixir Medical Corporation Southeast Asia

11/08/2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time
Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

https://www.tctmd.com/news/infinity-swedeheart-unlocking-device-bests-des-over-time?fbclid=IwY2xjawN7pb1leHRuA2FlbQIxMQBicmlkETF4eENUR1FvbmUxUFllQ2w4c3J0YwZhcHBfaWQQMjIyMDM5MTc4ODIwMDg5MgABHuaa13Bk0DCYpc35BQRvrxtZFLLlnhahI_KJC7BwsBHfb92KJsuXrHEbfZuh_aem_Vwv-3CmUHfes4LYwsYp6ew

Bioadaptor was designed to restore normal vessel function and reduce late stent-related complications. It’s working so far.

08/14/2025

The Dynamic Change of Coronary Artery Curvature (DC3) study looks at the geometry of vessel segments implanted with DynamX bioadaptor, compared to DES.

Take a look at Dr. Cheng-Hsuan Tsai’s presentation from EuroPCR to learn more about vessel geometry differences in segments treated with bioadaptors versus DES at 12-month follow-up:

https://lnkd.in/gFQ_KqkZ

Prof. Hsien-Li Kao, Prof. Wen-Jeng Lee, National Taiwan University Hospital

hashtag hashtag hashtag hashtag hashtag

06/15/2025

Mamas Mamas, Shigeru Saito, and David Erlinge discuss 3-year results for an "unlocking" device versus conventional DES.

These three-year results from the BIOADAPTOR RCT demonstrate that DynamX bioadaptor provides for a new class of treatment—with significant clinical benefit from six months when the bioadaptor mechanism of action is activated and sustained through long-term follow-up, including the hard clinical endpoint of cardiovascular death,” said Shigeru Saito (Shonan Kamakura General Hospital, Kamakura, Japan). “We also see the heightened importance of restoring haemodynamic modulation in the LAD vessel demonstrated by the large difference in clinical events in LAD lesions between the two treatment arms

Mamas Mamas, Shigeru Saito, and David Erlinge discuss 3-year results for an "unlocking" device versus conventional DES.

05/23/2025

EuroPCR25 - Novel DynamX Bioadaptor demonstrates a sustained reduction of device-related events from six-month to three-year follow-up compared to drug-eluting stents (DES).

Findings showed a significant reduction in TLF with the Novel DynamX Bioadapter at three-year follow-up compared to DES, as well as a reduction in cardiac death and clinically driven revascularisation. Furthermore, a significant treatment benefit was observed in left anterior descending artery lesions at three years.

https://www.radcliffecardiology.com/video-index/europcr-25-bioadaptor-rct-3y-outcomes

05/22/2025

Great news for heart patients! A 3-year study shared at EuroPCR 2025 shows the DynamX® bioadaptor significantly reduces heart-related issues compared to standard drug-eluting stents. The study found a "TLF rate" (a measure of serious heart events like heart attacks or the need for repeat procedures) was much lower with DynamX® (only 2.7%) compared to stents (7.2%). This means fewer complications for patients with DynamX®, with consistent benefits across all types of heart events measured, proving its lasting effectiveness over 3 years!

Here what it means to patients, imagine you have a heart problem, like a clogged artery, and doctors put a tiny device in your artery to keep it open. There are options: a standard drug elutting stent (a metal mesh tube) or a newer device called the DynamX® bioadaptor. A big 3-year study shared at a heart conference in 2025 compared these two.

The study looked at something called the "TLF rate," which tracks serious heart problems like heart attacks, the need for new procedures, or other complications. With the DynamX® bioadaptor, only 2.7% of patients had these issues, compared to 7.2% with standard stents. In simple terms, that means people with the DynamX® bioadaptor were much less likely to have serious heart problems over 3 years. It worked better across all kinds of heart issues they checked, showing it’s a reliable and effective option for keeping hearts healthier!

05/05/2025

𝗙𝗶𝗿𝘀𝘁 𝗟𝗶𝘁𝗵𝗶𝗫 𝗛𝗲𝗿𝘁𝘇 𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗜𝗩𝗟 𝗖𝗮𝘀𝗲 𝗶𝗻 𝗔𝘀𝗶𝗮
CVSKL becomes the first center in Asia to successfully treat a patient using the LithiX Hertz Contact Intravascular Lithotripsy (IVL) System — an innovative new technology for treating severely calcified coronary artery disease.
Heavy calcium buildup in the arteries often makes angioplasty procedures more difficult and riskier. The LithiX IVL System provides an innovative solution with its balloon-based design, featuring low-profile metal elements that effectively break down hardened plaque while minimising damage to the vessel.
With no need for external energy sources or capital equipment, the system streamlines complex procedures—making them faster, safer, and more efficient and delivering better long-term outcomes for patients.
At CVSKL, we are committed to delivering advanced cardiac care and enhancing patient’s lives by leading the way in adopting the latest innovative technologies like the LithiX Hertz Contact Intravascular Lithotripsy (IVL) System.
This milestone was made possible through the expertise and leadership of our consultant cardiologists — Dato’ Dr. Tamil Selvan, Datuk Dr. Rosli Mohd Ali, Dr. Choo Gim Hooi, Dr. Jayakhanthan, Dr. Al Fazir, Dr. Wan Faizal & Dr. Suren Thuraisingham— who continue to set new benchmarks in cardiovascular care.
To book an appointment, contact us today:
☎️ Call: +603 2276 7000
🌐 WhatsApp: +603 2276 7002
📧 Email: appointment@cvskl.com
Browse through our doctors profile here: https://www.cvskl.com/our-doctor/
Elixir Medical Corporation Southeast Asia Elixir Medical

04/25/2025

🚀 Exciting news! Elixir Medical is thrilled to attend with an action-packed program on Friday, April 25! Join us for:

🩺 Live Case & Lecture 7: Complex PCI

📍 Coronary Theater, Level 1

🕒 3:00 PM

Live from Cardiac Vascular Sentral Kuala Lumpur, Malaysia: Case #10 with 1st Operator Rosli Mohd Ali. Moderators: Jacques J. Koolen, Alan C. Yeung. Panelists: Jae Seok Bae, Gim-Hooi Choo, Polpat Euswas, and more!

📊 Acute Coronary Syndromes Session

📍 Abstract Zone 1, Exhibition Hall, Level 3

🕗 8:40 AM: Huan Yean Kang on outcomes with DynamX Bioadaptor Scaffold in ACS

🕘 8:50 AM: Kei Tung Wong on 12-month outcomes in STEMI with DynamX Bioadaptor

Moderators: Francisco Jose Ayala Riquelme, Jang-Whan Bae. Panelists: Chee Sin Khaw, Hong Nyun Kim, and others.

🔥 Saturday, April 26

🏆 Challenging Complex Case Competition 1

📍 Presentation Room 1, Level 1

🕙 9:00 AM: Chun Yat Fung presents long-term imaging analysis of Bioadaptor in CTO intervention.

Moderators: Francisco Jose Ayala Riquelme, Sang-Wook Kim. Panelists: Robert Thomas Ge**er, Sang-Ho Jo, and more.

Don’t miss this chance to explore cutting-edge innovations with Elixir Medical! 💡

04/11/2025

Elixir Medical Announces Launch of LithiX Hertz Contact (HC) Intravascular Lithotripsy System (IVL) in Europe

LithiX™ lithotripsy mechanism of action to create calcium fractures is based on the Hertz Contact Stress principle and does not require an external energy source or capital equipment, delivering the expected performance of IVL with additional versatility to treat complex calcified lesions based on the unique design.

“Lithotripsy, introduced in urology a few decades ago, has evolved to encompass mechanical and energy-based mechanisms of action to fragment calcium deposits while minimizing injury to soft tissue. Energy-based lithotripsy for intravascular use was adapted to deliver effective calcium modification while preventing injury to adjacent non-calcified vessel associated with manual devices,” said Motasim Sirhan, CEO of Elixir Medical. “With LithiX™, we created the first mechanical IVL platform capable of treating broad calcified lesion morphologies with great final outcomes, while minimizing injury to adjacent non-calcified vessel.”

https://www.globenewswire.com/news-release/2025/04/10/3059291/0/en/Elixir-Medical-Announces-Launch-of-LithiX-Hertz-Contact-HC-Intravascular-Lithotripsy-System-IVL-in-Europe.html

04/02/2025

Metallic stents are used to hold open narrowed arteries, but they can reduce the natural pulsing movement of the blood vessels.

In contrast, the DynamX Bioadaptor’s metallic helical strands are linked together by biodegradable parts that dissolve over a period of six months, unlocking the implant’s frame.

This allows the artery to move more freely and naturally, enhancing blood flow and reducing the risk of the vessel narrowing again.

NHCS has successfully treated some 100 patients with the DynamX Bioadaptor since it was introduced here in 2020.

In May 2024, Mr Chua Wah Guan was probably the first patient here to have electrosurgery to replace an aortic valve. Read more at straitstimes.com.

04/02/2025

Coronary heart disease finds young people's hearts (i.e., patients under 45 years old), and doctors interviewed point to inappropriate diet and lifestyle as the biggest cause. Young people love to stay up late, work pressure, coupled with lack of exercise and poor eating habits, it is easy to cause the "three high" problem, which in turn leads to coronary atherosclerosis; smoking will accelerate the worsening of coron
https://www.facebook.com/share/p/18sBDqfFCL/

03/21/2025

Why these 10 medical device makers are the most innovative in the world
Whether improving cardio care or reducing surgery recovery time, these medical device companies stand out.

In search of a better solution than stents, Elixir Medical has developed the DynamX, which has three helical strands linked together. It is coated in a biodegradable polymer that releases a medication for three months that helps the vessel heal. After six months, the polymer is absorbed by the body and the DynamX’s helical strands unlock and separate, allowing the blood vessel to move and function normally. Cleared for use in Europe, DynamX made strides toward use in the United States in 2024 while demonstrating its efficacy abroad. Elixir received the FDA’s breakthrough device designation for two uses—the DynamX BTK System, which treats narrowed or blocked blood vessels below the knee, and the DynamX Sirolimus-Eluting Coronary Bioadaptor System, which treats heart disease.


https://www.fastcompany.com/91269635/medical-devices-most-innovative-companies-2025

02/03/2025

National Heart Centre Singapore Advances Cardiac Care with the Revolutionary DynamX Bioadaptor at Singapore LIVE 2025

Singapore, 16 January 2025 – The National Heart Centre Singapore (NHCS) is proud to organise Singapore LIVE (SingLIVE) 2025, Asia's pre-eminent annual medical conference in cardiac interventions. Taking place from 16 to 18 January 2025 at Raffles City Convention Centre, SingLIVE 2025 will convene over 1,000 international delegates and 250 regional and international heart specialists for live demonstrations, discussions on groundbreaking innovations and immersive training sessions, aimed at enhancing care of patients with cardiovascular conditions in Singapore and beyond.

The 34th edition of SingLIVE reaffirms NHCS's commitment to pioneering advancements in cardiac care. Amongst many others, NHCS has led the forefront in transformative cardiac innovations including Electrosurgery, a cutting-edge technique in structural heart interventions, and the DynamX Bioadaptor, a revolutionary device to treat coronary artery disease. These developments, emerging from multidisciplinary expert collaboration, exemplify NHCS's mission to push the boundaries of interventional cardiology and significantly improve outcomes for patients with complex heart conditions.

https://www.singhealth.com.sg/rhs/news/patient-care/nhcs-advances-cardiac-care-with-singapore-live